The strategic biomarker roadmap for the validation of Alzheimer’s diagnostic biomarkers: methodological update

BACKGROUND: The 2017 Alzheimer’s disease (AD) Strategic Biomarker Roadmap (SBR) structured the validation of AD diagnostic biomarkers into 5 phases, systematically assessing analytical validity (Phases 1–2), clinical validity (Phases 3–4), and clinical utility (Phase 5) through primary and secondary...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Eur J Nucl Med Mol Imaging
Autori principali: Boccardi, Marina, Dodich, Alessandra, Albanese, Emiliano, Gayet-Ageron, Angèle, Festari, Cristina, Ashton, Nicholas J., Bischof, Gérard N., Chiotis, Konstantinos, Leuzy, Antoine, Wolters, Emma E., Walter, Martin A., Rabinovici, Gil D., Carrillo, Maria, Drzezga, Alexander, Hansson, Oskar, Nordberg, Agneta, Ossenkoppele, Rik, Villemagne, Victor L., Winblad, Bengt, Frisoni, Giovanni B., Garibotto, Valentina
Natura: Artigo
Lingua:Inglês
Pubblicazione: Springer Berlin Heidelberg 2021
Soggetti:
Original Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC8175304/
https://ncbi.nlm.nih.gov/pubmed/33688996
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00259-020-05120-2
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi